Notícias e Atividades da Rani Therapeutics

Rani Therapeutics é uma empresa listada sob o símbolo RANI (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Rani Therapeutics

• Talat Imran, Chief Executive Officer
• Abe Bassan, Director
• Mir Imran, Executive Chairman of the Board

Recentes movimentos de executivos em Rani Therapeutics

• Svai Sanford, Chief Financial Officer está prestes a deixar a empresa  (Notícia publicada em 18 de maio de 2026).
• Jesper Hoiland ingressará na Companhia como Head of Strategy em 26 de abr. de 2026  (Notícia publicada em 26 de março de 2026).
• Bella Vazquez antes Vice President, Human Resources, foi promovido a Senior Vice President, People & Administrative Services  (Notícia publicada em 30 de janeiro de 2026).

Clique aqui para ver outras movimentos em Rani Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Rani Therapeutics.

Rani Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Rani Therapeutics

• Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - Rani Therapeutics, LLC
• Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - Rani Therapeutics, LLC
• Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing - Rani Therap
• Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering - Rani Therapeutics, LLC
• Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery  - Rani Therapeutics, LLC
• Rani Therapeutics Announces Research Agreement with Chugai - Rani Therapeutics, LLC
• View more press releases Close

Redes sociais sobre Rani Therapeutics

• Rani Therapeutics na Wikipedia, Google News e Yahoo Finance
• Rani Therapeutics na LinkedIn, X (Twitter) e YouTube